Recruiting
Therapy cessation
RecruitingStudy of the effects of stopping elranatamab and teclistamab treatment in patients with multiple myeloma who have had a significant response to therapy.
Registered drugNo placebo
Study of the effects of stopping elranatamab and teclistamab treatment in patients with multiple myeloma who have had a significant response to therapy.
Registered drugNo placebo
- Disease:Therapy cessation
- Substances:ElranatamabTeclistamab
Countries:
Sweden
Sweden- Participants:18–64 years · 65+ years
- Substances:Elranatamab
- Sponsor:Vastra Gotalandsregionen